Inclusion Criteria:  Age ≥18 and ≤80 years; ECOG 0~1; Histologically or cytologically confirmed carcinoma of the bile duct or gallbladder; Imaging assessment of disease stage III/IVA/any TN1M0*; The main organs have good functions and the examination indexes meet the following requirements:  Blood routine test:  Hemoglobin ≥90 g/L (no blood transfusion within 14 days); Neutrophils count ≥1.5×10^9/L; Platelet count ≥80×10^9/L;  Biochemical tests:  Total bilirubin ≤2×ULN (upper limit of normal value); Blood alanine aminotransferase (ALT) or blood aspartate aminotransferase (AST) ≤ 2.5×ULN; Endogenous creatinine clearance rate ≥ 50 mL /min (Cockcroft-Gault formula);  Voluntarily signed the informed consent; Good compliance and family members are willing to cooperate with follow-up.  Exclusion Criteria:  Other uncured malignancies; Pregnant or lactating women, if the subject becomes pregnant during the study period, should withdraw from the clinical trial; Previous anti-tumor therapy for the disease in this study; Participated in other drug clinical trials within one month; Patients with known history of other systemic serious diseases before screening; Long-term unhealed wounds or incomplete healed fractures; Have a history of organ transplantation; Abnormal blood coagulation, with bleeding tendency (14 days before randomization must meet: INR within the normal range without the use of anticoagulants); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogs; The use of low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (not more than 100 mg daily) for prophylactic purposes is permitted, provided that INR is less than 1.5; The incidence of arterial/venous thrombosis events in the previous year, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism, was screened; People with a history of psychotropic substance abuse and unable to get rid of it or with mental disorders; Have a history of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;  12. Concomitant diseases that, in the Investigator's judgment, seriously endanger patient safety or affect patient completion of the study.